We are live on ! Find out more
Birchview Capital

Birchview Capital Portfolio holdings

AUM $173M Turnover 41.05%
1-Year Est. Return 89.27%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$189M
AUM Growth
+$9.21M
Cap. Flow
-$665K
Cap. Flow %
-0.35%
Top 10 Hldgs %
92.04%
Holding
44
New
3
Increased
9
Reduced
7
Closed
3
Avg Time Held
1.7 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$980K
2
AAAP icon
Advanced Accelerator Applications S.A.
AAAP
+$489K
3
XLRN
Acceleron Pharma
XLRN
+$435K
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$420K
5
CORT icon
Corcept Therapeutics
CORT
+$380K

Top Sells

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$859K
2
WKHS icon
Workhorse Group
WKHS
+$655K
3
MASI icon
Masimo
MASI
+$643K
4
TSRO
TESARO, Inc.
TSRO
+$550K
5
CTRA icon
Coterra Energy
CTRA
+$502K

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Energy 2.18%
3 Consumer Staples 0.56%
4 Miscellaneous 0.29%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$101M 53.25%
775,051
+8,000
+1% +$980K
2014 Q4
10 quarters
AXDX icon
2
DELISTED
Accelerate Diagnostics
AXDX
$59.7M 31.6%
218,380
– –
2014 Q4
10 quarters
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4.2M 2.22%
2,282,933
-470,000
-17% -$859K
2014 Q4
10 quarters
EQT icon
4
EQT Corp
EQT
$33B
$2.48M 1.31%
77,705
– –
2014 Q4
10 quarters
BIOL icon
5
DELISTED
Biolase, Inc.
BIOL
$1.25M 0.66%
103
– –
2014 Q4
10 quarters
OVV icon
6
Ovintiv
OVV
$17.6B
$1.16M 0.62%
26,460
– –
2014 Q4
10 quarters
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.9B
$1.16M 0.61%
25,200
– –
2015 Q3
7 quarters
OXFD
8
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.13M 0.6%
67,303
– –
2015 Q3
7 quarters
CORT icon
9
Corcept Therapeutics
CORT
$7.88B
$1.12M 0.59%
95,000
+35,000
+58% +$380K
2015 Q4
6 quarters
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$241M
$1.11M 0.59%
68,000
+14,000
+26% +$202K
2016 Q4
2 quarters
QDEL icon
11
QuidelOrtho
QDEL
$737M
$1.06M 0.56%
38,975
– –
2014 Q4
10 quarters
CFRX
12
DELISTED
ContraFect Corporation
CFRX
$1.05M 0.56%
906
– –
2015 Q2
8 quarters
YTEN icon
13
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$1.05M 0.56%
236
– –
2014 Q4
10 quarters
NXTM
14
DELISTED
NxStage Medical Inc.
NXTM
$857K 0.45%
34,200
+6,000
+21% +$149K
2014 Q4
10 quarters
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
$825K 0.44%
30,000
– –
2015 Q4
6 quarters
VCYT icon
16
Veracyte
VCYT
$1.96B
$823K 0.44%
98,767
+4,000
+4% +$32.6K
2016 Q3
3 quarters
AAAP icon
17
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$781K 0.41%
20,000
+13,000
+186% +$489K
2017 Q1
1 quarter
MASI icon
18
DELISTED
Masimo
MASI
$729K 0.39%
8,000
-7,000
-47% -$643K
2014 Q4
10 quarters
PRTK
19
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$727K 0.38%
30,150
+19,000
+170% +$420K
2016 Q2
4 quarters
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$727K 0.38%
5,200
-3,800
-42% -$550K
2015 Q4
6 quarters
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$655K 0.35%
7,000
-3,000
-30% -$184K
2017 Q1
1 quarter
MRK icon
22
Merck
MRK
$364B
$641K 0.34%
10,480
-5,240
-33% -$319K
2014 Q4
10 quarters
SIEN
23
DELISTED
Sientra, Inc.
SIEN
$615K 0.33%
6,330
– –
2015 Q3
7 quarters
QTNT
24
DELISTED
Quotient Limited Ordinary Shares
QTNT
$587K 0.31%
1,993
+538
+37% +$152K
2014 Q4
10 quarters
SITO
25
DELISTED
SITO MOBILE, LTD
SITO
$519K 0.27%
140,000
– –
2016 Q2
4 quarters
1
2

Similar funds

Ehrenkranz Partners
Ehrenkranz Partners New York $173M AUM 48.35% 1-Year Est. Return
Capstone Triton Financial Group
Capstone Triton Financial Group Oklahoma City, Oklahoma $174M AUM 45.26% 1-Year Est. Return
Doheny Asset Management
Doheny Asset Management Los Angeles, California $172M AUM 38.82% 1-Year Est. Return
SV
Stilwell Value New York $174M AUM 15.49% 1-Year Est. Return
Millbank Dartmoor Portsmouth
Millbank Dartmoor Portsmouth Asheville, North Carolina $176M AUM
Wilson & Boucher Capital Management
Wilson & Boucher Capital Management Moraga, California $170M AUM 28.6% 1-Year Est. Return
Legend Financial Advisors
Legend Financial Advisors Pittsburgh, Pennsylvania $176M AUM 57.06% 1-Year Est. Return
Black Maple Capital Management
Black Maple Capital Management Milwaukee, Wisconsin $176M AUM 9.49% 1-Year Est. Return

Birchview Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Birchview Capital held 44 positions worth $189M, up 5.1% from $180M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q2 2017 filing shows 3 new, 9 increased, 7 reduced and 3 closed positions. Its largest new stake was Acceleron Pharma: 15,000 shares worth $456K. The largest sale was Vermillion, Inc., an estimated $859K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2017 buy was Acceleron Pharma: 15,000 shares worth $456K.
  • Birchview Capital added most to Celgene Corp in Q2 2017, an estimated $980K increase.
  • Birchview Capital's biggest Q2 2017 reduction was Vermillion, Inc., cutting an estimated $859K.
  • Birchview Capital fully exited Coterra Energy in Q2 2017, selling an estimated $502K.
  • Birchview Capital's ten largest holdings make up 92% of its $189M portfolio in Q2 2017.
  • Birchview Capital opened 3 new positions and closed 3 in Q2 2017.
  • Birchview Capital's portfolio value rose 5.1% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2017, filed 8 Aug 2017.